Today’s podcast talks about RNA therapy optimization, AI-driven development, and collaborative models improving efficiency, scalability, and long-term outcomes.
Biopharma News
Advertisement
Today’s podcast spotlights major funding and a high-profile deal surrounding emerging multispecific immune-engaging biologics that demonstrate improved targeting precision and safety control across complex oncology and autoimmune indications.
Today’s podcast dives into Series A funding for T‑cell engagers and the advancement of multi-agonist metabolic therapies, which highlight innovation and platform-driven strategies in current biopharma pipelines.
Today’s podcast explores how late-stage clinical evidence supports extending established biologics into adjacent inflammatory diseases, reinforcing platform-based development strategies.
Today’s podcast covers Phase II trispecific antibody data and evolving ADC strategies, which highlight durable, patient-centric approaches reshaping next-generation oncology therapy pipelines.
In today’s podcast, integrated biomarker modeling and dual-pathway immune checkpoint modulation highlight evolving strategies to improve translational efficiency and durability in oncology trials.
INOVIO and Akeso’s combination of DNA tumor antigen priming and dual checkpoint inhibition exemplifies adaptive trial strategies for challenging glioblastoma therapy.
Today’s podcast covers how integrated development models and multi-pathway therapeutic design are signaling a shift toward scalable, system-ready biopharma innovation and translational efficiency.
Clinical trial execution and workforce strategy emerge as critical drivers of successful rare disease and advanced therapy development outcomes.
Today’s podcast highlights how sustained clinical efficacy data in alpha-thalassemia and ulcerative colitis highlight durability as a defining benchmark in modern biologic drug development.
Advertisement
Welcome to BioPharm Brief, a new podcast that synthesizes BioPharm International®’s coverage into concise, insight-driven updates on biopharmaceutical research, clinical and drug development trends, and evolving industry strategies.
Survey results show a shift in pharma industry sentiment from optimism to caution as rising insecurity offsets high satisfaction and intellectual engagement.
In Episode 31, industry veteran Deborah Dunsire goes behind the headlines to discuss the current state of innovation and evolving drug development landscape.
Digitalization is expected to reshape bioprocessing, supply chains, and quality systems for biopharma developers amid tariffs, geopolitics, and shifting capital flows, according to BioPlan Associates’ Eric Langer.
In the biopharma industry during 2025, quality, tariffs, MFN pricing, and strategic outsourcing deals drove innovation and investment.
Top BP Videos of 2025: An Intersection of AI, Innovation, and Compliance
Published: | Updated:
Our top 10 videos of the year cover AI, innovation, compliance, and sustainability in biopharma.
FounderNest CEO Feliz Gonzalez breaks down where the biotech market stands today and where it’s headed in 2026
The top 10 BioPharm International articles of 2025 highlight policy shifts, manufacturing innovation, and strategic partnerships.
Autolomous and Trenchant’s partnership, begun early in 2025, addresses unmet CGT manufacturing needs, including slashing costs and cutting timelines.
$17.5M biopharma alliance leverages CAMP4's tech, addressin protein under-expression in haploinsufficient disorders
In Episode 30, John Androsavich, Benjamin Fryer, and John Wilkerson go behind the headlines.
Chris Spivey explains how billions wasted on flawed near-infrared glucose sensing could have been avoided.
The third installment of the monthly BioPharma By the Numbers infographic series details batch failure trends in biopharma.
In Episode 29, John Androsavich, Benjamin Fryer and John Wilkerson go behind the top headlines from 2025.
The discussion in this Drug Digest video focuses on optimizing biopharmaceutical manufacturing and supply chain efficiency through the mastering of AI capabilities, data integration, and critical validation challenges.
ADC oncology platforms, FDA CNPV rapid review, and significant investment into US biologics manufacturing capacity led this week’s news.
David Dodd, GeoVax Labs, opines on why vaccine platform diversity is critical in the United States.
Five bio/pharma sector leaders dissect FDA’s CNPV pilot program.
News in the week shows biopharma development being redefined by programmable biology and accelerated FDA review, stressing quality compliance and market efficiency.
Five leaders from across the bio/pharma sector explore the opportunities and challenges posed by FDA’s CNPV pilot program.
Advertisement
Advertisement